ResMed (RMD) PT Bumped to $66 at Needham & Company Posts Q4

Go back to ResMed (RMD) PT Bumped to $66 at Needham & Company Posts Q4

Morgan Stanley Upgrades ResMed (RMD) to Overweight

July 31, 2015 10:01 AM EDT

Morgan Stanley upgraded ResMed (NYSE: RMD) from Equalweight to Overweight.

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $56.12 yesterday.

... More

Deutsche Bank Downgrades ResMed (RMD) to Sell

July 31, 2015 7:32 AM EDT

Deutsche Bank downgraded ResMed (NYSE: RMD) from Hold to Sell with a price target of $53.00 (from $61.00). The change follows Q4 results. Analyst David Low noted strong sales offset by GM weakness.

"After the incredible success of ResMeds AirSense range we are wary FY16... More

ResMed (RMD) Tops Q4 EPS by 3c, Revenue Beats

July 30, 2015 4:52 PM EDT

ResMed (NYSE: RMD) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $453.1 million versus the consensus estimate of $436.73 million.

For earnings history and earnings-related data on ResMed (RMD) click here.

... More